The global oncolytic virus treatment market is expected to grow at 27.29% during the forecast period (2021-2028). This market growth can be attributed to rising cancer incidences and the need to treat chronic diseases such as diabetes. According to World Health Organization (WHO) statistics, cancer is the leading cause of death globally and accounted for approximately 10 million deaths in 2020. Breast and lung cancer accounted for the largest proportion of new cases in 2020. They accounted for 2.26 million and 2.21 million cases, respectively. The increasing incidence of cancer has been steadily increasing around the globe due to an aging population and increased exposure to risk factors. This is driving the demand for more advanced cancer treatment and detection procedures. The market is expected to grow during the forecast period. Global oncolytic virus therapy revenue reached USD 160.4 million in 2019 and is expected to reach USD 1062.7 million by 2028.
The market will also see a rise in demand for targeted treatments, supported by rapid advances in cancer research and increased approvals of immuno-oncology drugs from the medical fraternities. The market growth is expected to be driven by rising healthcare spending. This percentage of GDP grew from 9.417% to 9.857% between 2013 and 2018…
Global Oncolytic Viral Therapy Market Regional Synopsis
The global market for oncolytic virus treatment is divided into North America and Europe, Asia Pacific, Europe, and the Rest of the World. The market in North America will hold the largest market share over the forecast period out of all the regions. The region’s market generated a revenue of USD 68.5 million in 2019, projected to grow to USD 509.4 million by 2028. The market is expected to grow due to rising awareness about different cancer treatments and the availability of advanced immuno-oncology drugs within the region. According to statistics from the American Cancer Society, there are approximately 1.9 million new cancer cases in the United States. In the same year, approximately 608570 cancer-related deaths are expected to occur in the country.
Europe is expected to generate the second-largest market revenue at USD 295.5 million by 2028. The largest market revenue in the region is expected to be from the United Kingdom, which will grow from USD 10.8 million in 2019 and reach USD 83.1 million by 2028.
| Oncolytic Virus Therapy Market Report Scope and Segmentation | |
|---|---|
| ATTRIBUTES | DETAILS |
| ESTIMATED YEAR | 2022 |
| BASE YEAR | 2021 |
| FORECAST YEAR | 2030 |
| HISTORICAL YEAR | 2017-2021 |
| UNIT | Value (USD Million/Billion) |
| BY REGION | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
Challenges and Growth Drivers in the Growth of the Global Oncolytic Viral Therapy Market
Growth Drivers
- Growing Cancer Cases Worldwide
- Targeted Therapy is in High Demand
- Rising Healthcare Expenditure Worldwide
- Rapid Advancements in Healthcare Research
Challenges
- Stringent Regulatory Standards
- High Cost of Cancer Drug Development
Global Oncolytic Viral Therapy Market Segmentation Synopsis
The oncolytic virus treatment market worldwide can be divided by type of therapy into HSV-based and adenovirus-based therapy. The adenovirus-based treatment for oncolytic viruses therapy segment held 30.2% of the global market in 2019 and is projected to continue growing its market share through 2028. The market can be divided into genetically engineered and oncolytic wild-type viruses. This segment will hold the largest market share for the entire forecast period. The market can also be segmented by virus type into head and neck cancers, lung cancers, liver cancers, pancreatic cancers, pancreatic cancers, breast cancers, colorectal carcinomas, Melanoma, esophageal cancer, and kidney cancer. Colorectal cancer is the segment with the highest market share, 11.1%. This segment is expected to generate significant market revenues by 2028. The market can be divided into two segments based on demography: adults and children. The market will gain the largest market share over the forecast period. The market is further segmented by end-user into hospitals, specialty clinics and cancer research institutes. In 2019, hospitals held 46.60% of the market.
Top Companies in the Market
The report includes detailed company profiles, including company overviews, key product offerings and financial performance. It also covers recent developments, SWOT analysis and risk analysis. Our report includes information on some of the most prominent players in the global oncolytic viral therapy market, including Amgen Inc., Sorrento Therapeutics, PsiOxus Therapeutics, Shanghai Sunway Biotech Co., Ltd., SillaJen, Oncolys BioPharma Inc., TILT Biotherapeutics Ltd., Oncorus, Inc., Takara Bio Inc., Myriad, Transgene SA, Lokon Pharma AB, Pfizer Inc.
Market Segmentation
- The Global Oncolytic Virus Therapy Market can be segmented according to application type, drug type, and therapy type.
- The market can be divided into Prostate, Ovarian Cancer and Breast Cancer. The largest market share is for Melanoma, as most cancer treatments are designed for Melanoma. In recent years, they have seen an increase in prostate cancer cases. This has also led to a steady rise in prostate cancer treatments.
- The market can be divided by drug class into Onyx-15 (Talimogene laherparepvec), Reolysin and RIVER. Talimogene laherparepvec was the dominant drug class, accounting for a large market share. This is due to its high penetration in cancer treatment.
Geographical Share
- The market can be divided by geography into North America and South America, Europe and the Asia Pacific. North America is the largest market worldwide, largely due to increased cancer cases and hectic lifestyles. The region’s growth has also supported a well-developed healthcare infrastructure.
Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Italy
- France
- UK
- Spain
- Poland
- Russia
- The Netherlands
- Norway
- Czech Republic
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Indonesia
- Malaysia
- Thailand
- Singapore
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Northern Africa
- Rest of MEA